A Phase 3 Program Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if
filgotinib helps to treat Axial Spondyloarthritis (axSpA) and is safe to use. In study
participants who are doing well with 200 mg filgotinib a day, the study will also be
comparing 200 mg with 100 mg filgotinib a day to see if the lower dose also helps to treat
axSpA.